← Back to Search

Intraocular Lens

enVista MX60EF for Cataract

N/A
Waitlist Available
Research Sponsored by Bausch & Lomb Incorporated
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 120 to day 180 after second eye implantation
Awards & highlights

Study Summary

This trial will test the safety and effectiveness of a new type of intraocular lens for people with cataracts.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 120 to day 180 after second eye implantation
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 120 to day 180 after second eye implantation for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Photopic monocular best-corrected distance visual acuity (BCDVA)
Photopic monocular distance-corrected intermediate visual acuity (DCIVA)
Photopic monocular distance-corrected near visual acuity (DCNVA)

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: enVista MX60EFExperimental Treatment1 Intervention
enVista MX60EF (trifocal) multifocal IOL (MIOL)
Group II: enVista MX60EActive Control1 Intervention
enVista MX60E monofocal IOL
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
enVista MX60EF
2018
N/A
~510

Find a Location

Who is running the clinical trial?

Bausch & Lomb IncorporatedLead Sponsor
251 Previous Clinical Trials
56,915 Total Patients Enrolled
47 Trials studying Cataract
15,502 Patients Enrolled for Cataract
Anya LoncaricStudy DirectorBausch health companies
39 Previous Clinical Trials
20,330 Total Patients Enrolled
5 Trials studying Cataract
1,751 Patients Enrolled for Cataract

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many research locations are actively conducting this trial?

"Presently, 22 medical centres are hosting this clinical trial; Birmingham, San Antonio and Pittsburgh being three of them. To reduce the burden of travel costs, participants should select a clinic closest to their residence."

Answered by AI

Is enrollment still available for this experiment?

"Per the information displayed on clinicaltrials.gov, this research project is presently not open for enrollment. The trial was initiated on May 31st 2018 and most recently revised on June 28th 2022; however, there are 124 other trials actively looking to include participants at this time."

Answered by AI

Who else is applying?

What state do they live in?
Florida
How old are they?
18 - 65
What site did they apply to?
Bausch Site 107
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Evaluate the Safety and Effectiveness of the enVista® One-Piece Hydrophobic Acrylic Trifocal Intraocular Lens
2018. "Evaluate the Safety and Effectiveness of the enVista® One-Piece Hydrophobic Acrylic Trifocal Intraocular Lens". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03603600.
~73 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top